Kehoehessellund6793

The European Commission requested the EFSA Panel on Plant Health to prepare and deliver risk assessments for commodities listed in Commission Implementing Regulation (EU) 2018/2019 as 'High risk plants, plant products and other objects'. Momordica fruits originating from countries where Thrips palmi is known to occur qualify as high risk plants. This Scientific Opinion covers the introduction risk for T. palmi posed by fruits of Momordica charantia L. imported from Mexico, taking into account the available scientific information, including the technical information provided by the National Service of Health, Safety and Agrifood Quality (Senasica) of Mexico. The risk mitigation measures proposed in the technical dossier from Mexico were evaluated taking into account the possible limiting factors. An expert judgement is given on the likelihood of pest freedom taking into consideration the potential pest pressure in the field, the risk mitigation measures acting on the pest in the field and in the packinghouse, including uncertainties associated with the assessment. For T. palmi on M. charantia fruits from Mexico, an expert judgement is given on the likelihood of pest freedom following the evaluation of the risk mitigation measures acting on T. palmi, including any uncertainties. The Expert Knowledge Elicitation indicated, with 95% certainty that between 9,492 and 10,000 M. charantia fruits per 10,000 will be free from T. palmi.The European Commission requested the EFSA Panel on Plant Health to prepare and deliver risk assessments for commodities listed in Commission Implementing Regulation (EU) 2018/2019 as 'High risk plants, plant products and other objects'. Momordica fruits originating from countries where Thrips palmi is known to occur qualify as high-risk plants. This Scientific Opinion covers the introduction risk for T. palmi posed by fruits of Momordica charantia L. LY3214996 ic50 imported from Sri Lanka, taking into account the available scientific information, including the technical information provided by the National Plant Quarantine Service of Sri Lanka. The risk mitigation measures proposed in the technical dossier from Sri Lanka were evaluated taking into account the possible limiting factors. An expert judgement is given on the likelihood of pest freedom taking into consideration the potential pest pressure in the field, the risk mitigation measures acting on the pest in the field and in the packing house, including uncertainties associated with the assessment. For T. palmi on M. charantia fruits from Sri Lanka, an expert judgement is given on the likelihood of pest freedom following the evaluation of the risk mitigation measures acting on T. palmi, including any uncertainties. The Expert Knowledge Elicitation indicated, with 95% certainty that between 9831 and 10,000 M. charantia fruits/10,000 will be free from T. palmi.The European Commission requested the EFSA Panel on Plant Health to prepare and deliver risk assessments for commodities listed in Commission Implementing Regulation (EU) 2018/2019 as 'High risk plants, plant products and other objects'. M. charantia fruits originating from countries where Thrips palmi is known to occur qualify as high-risk plants. This Scientific Opinion covers the introduction risk for T. palmi posed by fruits of Momordica charantia L. imported from Suriname, taking into account the available scientific information, including the technical information provided by the National Plant Protection Organization of Suriname. The risk mitigation measures proposed in the technical dossier from Suriname were evaluated taking into account the possible limiting factors. An expert judgement is given on the likelihood of pest freedom taking into consideration the potential pest pressure in the field, the risk mitigation measures acting on the pest in the field and in the packinghouse, including uncertainties associated with the assessment. For T. palmi on M. charantia fruits from Suriname, an expert judgement is given on the likelihood of pest freedom following the evaluation of the risk mitigation measures acting on T. palmi, including any uncertainties. The Expert Knowledge Elicitation indicated, with 95% certainty that between 8,652 and 10,000 M. charantia fruits per 10,000 will be free from T. palmi.The European Commission requested the EFSA Panel on Plant Health to prepare and deliver risk assessments for commodities listed in Commission Implementing Regulation (EU) 2018/2019 as 'High risk plants, plant products and other objects'. Momordica fruits originating from countries where Thrips palmi is known to occur qualify as high risk plants. This Scientific Opinion covers the introduction risk for T. palmi posed by fruits of Momordica charantia L. imported from Honduras, taking into account the available scientific information, including the technical information provided by the National Service of Agrifood Health and Safety (SENASA) of Honduras. The risk mitigation measures proposed in the technical dossier from Honduras were evaluated taking into account the possible limiting factors. An expert judgement is given on the likelihood of pest freedom taking into consideration the potential pest pressure in the field, the risk mitigation measures acting on the pest in the field and in the packinghouse, including uncertainties associated with the assessment. For T. palmi on M. charantia fruits from Honduras, an expert judgement is given on the likelihood of pest freedom following the evaluation of the risk mitigation measures acting on T. palmi, including any uncertainties. The Expert Knowledge Elicitation indicated, with 95% certainty that between 9,406 and 10,000 M. charantia fruits per 10,000 will be free from T. palmi.A retrospective cumulative risk assessment of dietary exposure to pesticide residues was conducted for chronic inhibition of acetylcholinesterase. The pesticides considered in this assessment were identified and characterised in a previous scientific report on the establishment of cumulative assessment groups of pesticides for their effects on the nervous system. The exposure assessments used monitoring data collected by Member States under their official pesticide monitoring programmes in 2016, 2017 and 2018, and individual food consumption data from 10 populations of consumers from different countries and from different age groups. Exposure estimates were obtained by means of a two-dimensional probabilistic model, which was implemented in SAS ® software. The characterisation of cumulative risk was supported by an uncertainty analysis based on expert knowledge elicitation. For each of the 10 populations, it is concluded with varying degrees of certainty that cumulative exposure to pesticides contributing to the chronic inhibition of acetylcholinesterase does not exceed the threshold for regulatory consideration established by risk managers.Glucose transporter (GLUT)-mediated transcytosis has been validated as an efficient method to cross the blood-brain barrier and enhance brain transport of nanomedicines. However, the transcytosis process remains elusive. Glycopeptide-modified nanodisks (Gly-A7R-NDs), which demonstrated high capacity of brain targeting via GLUT-mediated transcytosis in our previous reports, were utilized to better understand the whole transcytosis process. Gly-A7R-NDs internalized brain capillary endothelial cells mainly via GLUT-mediated/clathrin dependent endocytosis and macropinocytosis. The intracellular Gly-A7R-NDs remained intact, and the main excretion route of Gly-A7R-NDs was lysosomal exocytosis. Glycosylation of nanomedicine was crucial in GLUT-mediated transcytosis, while morphology did not affect the efficiency. This study highlights the pivotal roles of lysosomal exocytosis in the process of GLUT-mediated transcytosis, providing a new impetus to development of brain targeting drug delivery by accelerating lysosomal exocytosis.Ulcerative colitis is a global health problem, affecting millions of individuals worldwide. As an inflammatory condition localised in the large intestine, rectal delivery of immunosuppressive therapies such as tacrolimus is a promising strategy to maximise drug concentration at the site of action whilst minimising systemic side effects. Here, for the first time, self-supporting 3D-printed tacrolimus suppositories were prepared without the aid of moulds using a pharmaceutical semi-solid extrusion (SSE) 3D printer. The suppositories were printed vertically in three different sizes using combinations of two lipid pharmaceutical excipients (Gelucire 44/14 or Gelucire 48/16) and coconut oil. Although both suppository formulations had the appropriate viscosity characteristics for printing, the Gel 44 formulation required less energy and force for extrusion compared to the Gel 48 system. The Gel 44 disintegrated more rapidly but released tacrolimus more slowly than the Gel 48 suppositories. Although the tacrolimus release profiles were significantly different, both suppository systems released more than 80% drug within 120 min. DSC and XRD analysis was inconclusive in determining the solid-state properties of the drug in the suppositories. In summary, this article reports on the fabrication of 3D printed self-supporting suppositories to deliver personalised doses of a narrow therapeutic index drug, with potential benefits for patients with ulcerative colitis.Currently, the cancer immunotherapy has made great progress while antitumor vaccine attracts substantial attention. Still, the selection of adjuvants as well as antigens are always the most crucial issues for better vaccination. In this study, we proposed a biomimetic antitumor nanovaccine based on biocompatible nanocarriers and tumor cell membrane antigens. Briefly, endogenous calcium pyrophosphate nanogranules with possible immune potentiating effect are designed and engineered, both as delivery vehicles and adjuvants. Then, these nanocarriers are coated with lipids and B16-OVA tumor cell membranes, so the biomembrane proteins can serve as tumor-specific antigens. It was found that calcium pyrophosphate nanogranules themselves were compatible and possessed adjuvant effect, while membrane proteins including tumor associated antigen were transferred onto the nanocarriers. It was demonstrated that such a biomimetic nanovaccine could be well endocytosed by dendritic cells, promote their maturation and antigen-presentation, facilitate lymph retention, and trigger obvious immune response. It was confirmed that the biomimetic vaccine could induce strong T-cell response, exhibit excellent tumor therapy and prophylactic effects, and simultaneously possess nice biocompatibility. In general, the present investigation might provide insights for the further design and application of antitumor vaccines.Systemic chemotherapy of breast cancer is commonly delivered as a large dose and has toxic side effects. Local chemotherapy would overcome the shortcomings of systemic reconstruction and could play an important role in breast cancer surgery according to personalized demand. The application of three-dimensional (3D) printing technology makes personalized customization possible. We designed and prepared a prosthesis containing paclitaxel (PTX) and doxorubicin (DOX) microspheres (PPDM) based on 3D printing to prevent tumor recurrence and metastasis after breast conserving surgery. Polydimethysiloxane has good biocompatibility and was used as a drug carrier in this study. The average particle size of the PTX and DOX microspheres were approximately 3.1 µm and 2.2 µm, respectively. The drug loading of PTX and DOX microspheres was 4.2% and 2.1%, respectively. In vitro drug release studies demonstrated that the 3D-printed prosthesis loaded with PTX and DOX microspheres could release the drugs continuously for more than 3 weeks and thereby suppress cancer recurrence with reduced side effects.